Literature DB >> 29685781

The regulation of JAKs in cytokine signaling and its breakdown in disease.

Henrik M Hammarén1, Anniina T Virtanen2, Juuli Raivola2, Olli Silvennoinen3.   

Abstract

The JAK-STAT signal transduction pathway is responsible for mediating signals of over fifty cytokines, growth factors and hormones. Signaling through the JAK-STAT pathway is regulated on multiple levels, including intramolecular regulation by the JAK pseudokinase domain, and intermolecular regulation by a host of regulatory proteins. The advent of accessible genomic tools have provided a wealth of information on disease-associated mutations in the JAK-STAT pathway and its regulatory components. The vast number of these mutations in diseases ranging from immunodeficiencies and obesity to many cancers highlight the importance of correct regulation of JAK-STAT signaling for biological processes such as hematopoiesis, regulation of the immune system, metabolism, and growth. Simultaneously, JAK inhibitors are gaining traction in clinical use, both for treatment of diseases driven by JAK mutations, and for a host of inflammatory disorders, in which proinflammatory cytokine signaling through the JAK-STAT pathway is an integral part of pathogenesis. The elucidation of molecular mechanisms in the pathogenesis of complex diseases has also, however, brought the limitations of our current understanding on the regulation of cytokine signaling to the foreground. Indeed, deeper understanding of these regulatory mechanisms are a prerequisite for the development of the next generation of pharmacological modulators of the JAK-STAT pathway. In this review we discuss the current state of knowledge of the intra- and intermolecular regulation of the JAK-STAT pathway, with a focus on diseases arising from disruptions in the regulatory apparatus.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cancer; Cytokine signaling; Janus kinase (JAK); Mutation; Myeloproliferative neoplasm (MPN)

Mesh:

Substances:

Year:  2018        PMID: 29685781     DOI: 10.1016/j.cyto.2018.03.041

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  52 in total

1.  STAT5: a Target of Antagonism by Neurotropic Flaviviruses.

Authors:  Matthew G Zimmerman; James R Bowen; Circe E McDonald; Ellen Young; Ralph S Baric; Bali Pulendran; Mehul S Suthar
Journal:  J Virol       Date:  2019-11-13       Impact factor: 5.103

2.  Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.

Authors:  Henrik M Hammarén; Anniina T Virtanen; Bobin George Abraham; Heidi Peussa; Stevan R Hubbard; Olli Silvennoinen
Journal:  J Allergy Clin Immunol       Date:  2018-08-06       Impact factor: 10.793

3.  Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations.

Authors:  Stephan Wilmes; Maximillian Hafer; Joni Vuorio; Julie A Tucker; Hauke Winkelmann; Sara Löchte; Tess A Stanly; Katiuska D Pulgar Prieto; Chetan Poojari; Vivek Sharma; Christian P Richter; Rainer Kurre; Stevan R Hubbard; K Christopher Garcia; Ignacio Moraga; Ilpo Vattulainen; Ian S Hitchcock; Jacob Piehler
Journal:  Science       Date:  2020-02-07       Impact factor: 47.728

Review 4.  Cytokine receptor splice variants in hematologic diseases.

Authors:  Borwyn Wang; Hrishikesh Mehta
Journal:  Cytokine       Date:  2019-12-06       Impact factor: 3.861

Review 5.  Cardiovascular Disease, Aging, and Clonal Hematopoiesis.

Authors:  Megan A Evans; Soichi Sano; Kenneth Walsh
Journal:  Annu Rev Pathol       Date:  2019-11-05       Impact factor: 23.472

6.  14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia.

Authors:  Danika Di Giacomo; Roberta La Starza; Paolo Gorello; Fabrizia Pellanera; Zeynep Kalender Atak; Kim De Keersmaecker; Valentina Pierini; Christine J Harrison; Silvia Arniani; Martina Moretti; Nicoletta Testoni; Giovanna De Santis; Giovanni Roti; Caterina Matteucci; Renato Bassan; Peter Vandenberghe; Stein Aerts; Jan Cools; Beat Bornhauser; Jean-Pierre Bourquin; Rocco Piazza; Cristina Mecucci
Journal:  Blood       Date:  2021-09-02       Impact factor: 22.113

Review 7.  Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies.

Authors:  Vincenzo Nasillo; Giovanni Riva; Ambra Paolini; Fabio Forghieri; Luca Roncati; Beatrice Lusenti; Monica Maccaferri; Andrea Messerotti; Valeria Pioli; Andrea Gilioli; Francesca Bettelli; Davide Giusti; Patrizia Barozzi; Ivana Lagreca; Rossana Maffei; Roberto Marasca; Leonardo Potenza; Patrizia Comoli; Rossella Manfredini; Antonino Maiorana; Enrico Tagliafico; Mario Luppi; Tommaso Trenti
Journal:  Int J Mol Sci       Date:  2021-02-14       Impact factor: 5.923

Review 8.  Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer.

Authors:  Fanglong Wu; Jin Yang; Junjiang Liu; Ye Wang; Jingtian Mu; Qingxiang Zeng; Shuzhi Deng; Hongmei Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-06-10

Review 9.  Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?

Authors:  Klara Klein; Dagmar Stoiber; Veronika Sexl; Agnieszka Witalisz-Siepracka
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

Review 10.  The thrombopoietin receptor: revisiting the master regulator of platelet production.

Authors:  Ian S Hitchcock; Maximillian Hafer; Veena Sangkhae; Julie A Tucker
Journal:  Platelets       Date:  2021-06-07       Impact factor: 3.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.